Naicker, N.Sigal, A.Naidoo, K.2024-03-222024-03-222020-04-29Naicker N, Sigal A & Naidoo K. Metformin as host-directed therapy for TB treatment: Scoping review. Front Microbiol. 2020 Apr 29,11:435. doi: 10.3389/fmicb.2020.00435.10.3389/fmicb.2020.00435https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201016/https://hdl.handle.net/11288/595676Tuberculosis (TB) disease is an international health concern caused by the bacteria Mycobacterium tuberculosis (Mtb). Evolution of multi-drug-resistant strains may cause bacterial persistence, rendering existing antibiotics ineffective. Hence, development of new or repurposing of currently approved drugs to fight Mtb in combination with existing antibiotics is urgently needed to cure TB which is refractory to current therapy. The shortening of TB therapy and reduction in lung injury can be achieved using adjunctive host-directed therapies. There is a wide range of probable candidates which include numerous agents permitted for the treatment of other diseases. One potential candidate is metformin, a Food and Drug Administration (FDA)-approved drug used to treat type 2 diabetes mellitus (DM). However, there is a scarcity of evidence supporting the biological basis for the effect of metformin as a host-directed therapy for TB. This scoping review summarizes the current body of evidence and outlines scientific gaps that need to be addressed in determining the potential role of metformin as a host-directed therapy.enAttribution 3.0 United Stateshttp://creativecommons.org/licenses/by/3.0/us/Mycobacterium tuberculosisTuberculosisMetforminHost-directed therapyAdjuvantArticleFrontiers in Microbiology